Aevis Victoria stock
AEVS.SWSIXAevis Victoria S.A., HealthcareISIN CH0478634105
34Score 34 out of 100, Weak
Price and trend
56 / 100
Price history
+11% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 4.9% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 38).
The price is 11% below its 52-week high. Largest decline in 20 years: 72% (February 2007 to March 2009).
Chart figures for advanced users
- SMA 50$17.44
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.25
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)38
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.86
- The lowest closing price of the last twelve months.
- Resistance$19.22
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Aevis Victoria S.A. belongs to the Medical (Care Facilities) industry (Switzerland) and, with a market value of $1.45B, is number 39 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.37B (up 12.1% year on year) and a loss of $24.23M.
- MEQIRI Score 34 out of 100 (Weak): rank 641 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Loss-makingLoss of $22.71M over the last 12 months.Fundamentals 17
- High debtDebt 1.81 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 32
The score is held back by profitability and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
OvervaluedClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 19.6% on the twelve months before. Revenue has grown strongly since 2006, at around 29% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 17%, operating −5%, net −2%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- No date announced.
- Last reported
- 17 Sep 2026EPS reported $0.08 (expected $0.22)below expectations
Analyst estimates
- Earnings per share
- $0.16+17.2%
- Revenue
- $1.31B−0.6%
- Earnings per share
- $0.40−1.4%
- Revenue
- $1.35B−0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Aevis Victoria
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- AmbeaAMBEA.ST $1.64B70
- Astrana HealthASTH $1.63B54
- U.S. Physical TherapyUSPH $1.49B55
- AMN Healthcare ServicesAMN $1.47B65
- ClarianeCLARI.PA $1.37B39
- Nutex HealthNUTX $1.3B74
- Innovage HoldingINNV $1.3B59
- Pennant GroupPNTG $1.29B54
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2020)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.